We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-20.62%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.84B
AUM Growth
-$1.19B
Cap. Flow
+$214M
Cap. Flow %
5.56%
Top 10 Hldgs %
54.93%
Holding
140
New
25
Increased
22
Reduced
18
Closed
27

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$104M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$59.7M
3
ZYME icon
Zymeworks
ZYME
+$47.4M
4
NVRO
NEVRO CORP.
NVRO
+$39.5M
5
BDTX icon
Black Diamond Therapeutics
BDTX
+$33.6M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$152M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$78.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$53.8M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$37.3M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$23.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.4%
2 Financials 0.28%
3 Technology 0.27%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
26
DELISTED
Molecular Templates, Inc.
MTEM
$32.9M 0.86%
164,942
– –
ALBO
27
DELISTED
Albireo Pharma Inc
ALBO
$31.9M 0.83%
1,960,139
+255,809
+15% +$5.62M
AGIO icon
28
Agios Pharmaceuticals
AGIO
$2.08B
$31.9M 0.83%
900,000
– –
VAPO
29
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$31.4M 0.82%
208,758
-9,213
-4% -$832K
RCKT icon
30
Rocket Pharmaceuticals
RCKT
$343M
$30.5M 0.8%
2,189,010
-50,231
-2% -$995K
ALLO icon
31
Allogene Therapeutics
ALLO
$625M
$30M 0.78%
1,543,790
– –
AGRX
32
DELISTED
Agile Therapeutics
AGRX
$29.6M 0.77%
7,960
+2,000
+34% +$11.5M
DBVT
33
DBV Technologies
DBVT
$813M
$28.7M 0.75%
731,781
+295,000
+68% +$26.5M
ARNA
34
DELISTED
Arena Pharmaceuticals Inc
ARNA
$28.4M 0.74%
675,129
-278,000
-29% -$12.7M
PRVB
35
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$27.7M 0.72%
3,011,574
+90,000
+3% +$1.16M
BDTX icon
36
Black Diamond Therapeutics
BDTX
$95.1M
$27.6M 0.72%
+1,104,656
New +$33.6M
COLL icon
37
Collegium Pharmaceutical
COLL
$1.18B
$25.3M 0.66%
1,551,722
+1,130,450
+268% +$23.3M
CTMX icon
38
CytomX Therapeutics
CTMX
$690M
$25M 0.65%
3,253,923
– –
TBPH icon
39
Theravance Biopharma
TBPH
$873M
$23.1M 0.6%
+1,000,000
New +$25M
UROV
40
DELISTED
Urovant Sciences Ltd.
UROV
$21.8M 0.57%
2,366,831
-40,100
-2% -$482K
CNCE
41
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$19.5M 0.51%
2,150,641
– –
VYNE icon
42
VYNE Therapeutics
VYNE
$17.5M 0.45%
+1,844
New +$28.9M
RGNX icon
43
Regenxbio
RGNX
$616M
$17.1M 0.45%
508,000
-100,000
-16% -$4.17M
NEPT
44
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$15.7M 0.41%
9,598
– –
TPTX
45
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$15.4M 0.4%
349,890
-87,500
-20% -$4.65M
STOK icon
46
Stoke Therapeutics
STOK
$1.84B
$15.4M 0.4%
671,978
– –
DNLI icon
47
Denali Therapeutics
DNLI
$3.79B
$14.9M 0.39%
+850,000
New +$17.7M
TXG icon
48
10x Genomics
TXG
$5.88B
$13.8M 0.36%
220,000
– –
PODD icon
49
Insulet
PODD
$11.8B
$13.7M 0.36%
+82,733
New +$15.1M
RVNC
50
DELISTED
Revance Therapeutics, Inc.
RVNC
$13.7M 0.36%
925,000
+104,623
+13% +$2.16M
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2020 Portfolio in Review

As of Q1 2020, Perceptive Advisors held 140 positions worth $3.84B, down 24% from $5.03B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Perceptive Advisors deployed $214M of net new capital in Q1 2020, opening 25 new positions and adding to 22 existing holdings. Its largest new stake was Gilead Sciences: 1,500,000 shares worth $11.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Momenta Pharmaceuticals, Inc., an estimated $78.1M trimmed.

  • Perceptive Advisors's largest Q1 2020 buy was Gilead Sciences: 1,500,000 shares worth $11.2M.
  • Perceptive Advisors added most to Iovance Biotherapeutics in Q1 2020, an estimated $59.7M increase.
  • Perceptive Advisors's biggest Q1 2020 reduction was Momenta Pharmaceuticals, Inc., cutting an estimated $78.1M.
  • Perceptive Advisors fully exited Amarin Corp in Q1 2020, selling an estimated $152M.
  • Perceptive Advisors's ten largest holdings make up 55% of its $3.84B portfolio in Q1 2020.
  • Perceptive Advisors opened 25 new positions and closed 27 in Q1 2020.
  • Perceptive Advisors's portfolio value fell 24% quarter-over-quarter to $3.84B.

Based on Perceptive Advisors's 13F filing for Q1 2020, filed 15 May 2020.